Zymeworks Inc.ZYMEEarnings & Financial Report

Nasdaq · pharmaceutical industry

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

Revenue

$27.6M

Gross Profit

N/A

Operating Profit

$-22.1M

Net Profit

$-19.6M

Gross Margin

N/A

Operating Margin

-80.1%

Net Margin

-71.0%

YoY Growth

72.6%

EPS

$-0.26

Financial Flow

Zymeworks Inc. Q3 2025 Financial Summary

Zymeworks Inc. reported revenue of $27.6M for Q3 2025, with a net profit of $-19.6M (-71.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$27.6M
Net Profit	$-19.6M
Gross Margin	N/A
Operating Margin	-80.1%
Report Period	Q3 2025

Zymeworks Inc. Annual Revenue by Year

Zymeworks Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $76.3M).

Year	Annual Revenue
2024	$76.3M
2023	$76.0M
2022	$412.5M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$16.9M	$10.0M	$19.2M	$16.0M	$31.0M	$27.1M	$48.7M	$27.6M
YoY Growth	-95.8%	-71.8%	174.8%	-3.1%	83.3%	170.3%	153.2%	72.6%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$580.9M	$553.8M	$515.6M	$487.2M	$463.1M	$425.5M	$408.4M	$397.3M
Liabilities	$116.1M	$115.8M	$109.5M	$120.2M	$124.3M	$100.6M	$73.9M	$77.2M
Equity	$464.8M	$438.0M	$406.2M	$367.0M	$338.8M	$325.0M	$334.5M	$320.1M